Reformulary Group

In 2019, Reformulary Group was selected a CIX TOP 20 Early Innovative Canadian technology start-up, and in 2018, Reformulary Group won the TELUS Outstanding Product Achievement Award. Founded in 2011 by Helen Stevenson, CEO, Reformulary Group is an expert-led healthcare technology company focused on helping Canadians and companies make sense of medicine. The Company’s proprietary drug list, the Reformulary®, is a subscription-based product offered to Canadian employers, unions, and associations. The Reformulary provides Canadians with valuable comparative drug information, reviewed, and vetted by an independent committee of doctors and pharmacists from across Canada. Through the Company’s formulary business, they have amassed proprietary - and acquired - datasets that they are connecting in new, insightful, and revenue-generating ways. Data-as-a-Product solutions include rapid access data insights to help pharma make more informed decisions, and a predictive modelling tool that charts the pipeline of new high-cost drugs and predicts the impact on drug plans. Reformulary Group is a privately held high growth-stage company headquartered in downtown Toronto. For more information visit www.reformulary.com.